Newsletter · · Ashutosh Agarwal

Pharma Deals Run Through China While Obesity and Cancer Data Reset Expectations - Weekly Pharma/Biotech Podcast Recap - Week of October 11, 2026

Weekly Pharma/Biotech Podcast Recap for the week of October 4 to 11, 2026. A synthesis of investor and operator podcasts on a licensing and buyout wave running through China, the shrunken GLOBE and GUARD drug-pricing models, the obesity-drug race between Lilly and Novo, fresh cancer and cell-therapy data, and a biotech tape where the index is up but specialists are not.

Weekly Pharma/Biotech Podcast Recap

Week of October 11, 2026: Pharma Deals Run Through China While Obesity and Cancer Data Reset Expectations


The week in one paragraph: Deals were the main story this week. In seven days drugmakers signed a run of licensing deals and buyouts, and many of them went through China. Novartis put up $575 million upfront for an early-stage mRNA drug from China's Abogen. Sanofi paid Regeneron $1 billion just to keep looking for the next Dupixent. Shionogi bought IntraBio for $2 billion. AstraZeneca's $2 billion stake in Summit Therapeutics was still being picked apart. On the science side, Genmab and AbbVie's lymphoma drug Epkinly beat expectations by a wide margin. Novo Nordisk's CagriSema "beat Mounjaro" headline turned out to rest on low doses. In Washington the fight shifted from drug prices to peptides: HHS is preparing to let compounding pharmacies sell unapproved peptides even though FDA reviewers object, and FDA nominee Heidi Overton's confirmation looks stuck until after the midterms. Under the surface, the biotech stock index (the XBI) is up 23% this year, yet STAT's Adam Feuerstein says specialist biotech investors are "seriously depressed."

(1) Dominant Themes

Theme 1: A week packed with deals, and most of them are early bets

Three podcasts spent long segments on deals. The size of the upfront checks surprised the hosts.

  • Novartis and Abogen, up to $7.8 billion. On BioSpace's weekly show, Heather McKenzie explained that the drug is an mRNA medicine that tells the patient's own body to make a "T-cell engager." That is an antibody that pulls the immune system's T cells onto disease-causing B cells and kills them. Abogen says making it inside the body could lower the risk of cytokine release syndrome, a dangerous immune overreaction common with these drugs. The companies pointed it at autoimmune diseases. Host Jeff Axt flagged the $575 million upfront payment as "a chunk of change just for the upfront payment" (BioSpace).
  • Sanofi pays Regeneron $1 billion to stay together. Gabrielle Masson said Sanofi renewed its decades-long partnership with $1 billion upfront and up to $7 billion more in milestone payments to develop four next-generation antibodies. The goal is a successor to Dupixent, the eczema and asthma drug that was the fourth best-selling drug of 2025 at nearly $18 billion. A key US Dupixent patent expires in 2031. The deal also settled a lawsuit Regeneron filed last year claiming Sanofi held back Dupixent sales information. Axt's reaction: "They had a whole legal dispute. They're like, we're all good now. We'll just throw another several billion at them" (BioSpace).
  • Shionogi buys IntraBio for $2 billion. IntraBio's drug Aqneursa was first approved in September 2024 for Niemann-Pick disease type C, a rare inherited disorder. A few weeks ago it was also approved as the first-ever treatment for ataxia-telangiectasia, a fatal disease in which part of the brain slowly breaks down. Jefferies sees about $1 billion in global peak sales (BioSpace). Asked on Bloomberg Intelligence whether Shionogi will become a regular buyer, Sam Fazeli said: "I would doubt it... famous last words" (Bloomberg Intelligence).
  • Smaller deals. Lilly widened its partnership with Gate Bioscience by up to $870 million, on top of the $856 million it committed last year. The work is on "molecular gates," small-molecule drugs meant to remove hard-to-reach proteins outside cells. CSL put up $355 million upfront and up to $1.2 billion in total with Alentis Therapeutics for kidney and liver disease (BioSpace).
  • The full-year picture. On CNBC's Fast Money, John Flavin, founder and CEO of Portal Innovations, put 2026 pharma deal-making at "around $135 billion in deals, mainly bolt-on deals, $1 to $10 billion deals, not the big mega mergers." He called that "good for biotech because biotech is usually going to be priced in that $1 to $10 billion category" (Fast Money).
  • But the quarter slowed. BioSpace counted 22 acquisitions in Q3 versus 31 in Q2. The biggest was Vertex buying Crinetics in July for about $10 billion, which moves Vertex beyond cystic fibrosis into hormone diseases (BioSpace).

Theme 2: China is now where big pharma shops for new drugs, and Washington is watching

  • A record year for China deals. On BioCentury This Week, Lauren Martz said her team's count of deals between 21 big drugmakers and China-based biotechs is already nine deals ahead of all of last year, and it is only October. Last week's three deals (Merck, Novo and Novartis) each had upfront payments of $300 million or more and total values over $2 billion. Only one of the three, Abogen, had any human data at all; the other two were still preclinical, meaning not yet tested in people (BioCentury This Week).
  • Wider than antibodies and cancer. Martz said the deals now cover "three different modalities and three different disease areas," where a few years ago they were mostly antibody cancer drugs. One example is Merck licensing a KRAS G12D "molecular glue" from a company called Cybrunch. KRAS is a cancer-driving gene that was long thought "undruggable," and a molecular glue is a small molecule that makes two proteins stick together so the cancer protein gets switched off or broken down (BioCentury This Week).
  • The political risk is co-development, not licensing. BioCentury's Washington editor Steve Usdin said congressional staff and Treasury officials worry less about Western companies buying Chinese assets and more about deals where the two sides develop and sell a drug together. "If we see big co-development deals, we see more of them, that's likely to fuel... more restrictive rules" when Treasury writes rules folding biotech into the COINS Act, an outbound-investment law aimed at China (BioCentury This Week).
  • The numbers behind the shift. On Fast Money, Flavin said "roughly 30 percent of deals that are happening and licensing right now in pharma are coming from China." He said China's share of global drug development went from "about 8 percent in 2015... to about 32 percent today," while the US fell "from about 48 percent... to about 37 percent." He blamed the US itself: "NIH is moving too slow to fund... FDA has not been a very transparent institution... All these scientists that used to come to the U.S. to study... are all kind of going home" (Fast Money).
  • Chinese drugs going global is not the same as Chinese companies going global. BioCentury's Selina Koch pointed to a guest piece by Frank Le Deu, a longtime McKinsey China leader. His argument is that until a Chinese company sells in the US on its own books, "we're never really going to get a truly global... company from inside China" (BioCentury This Week).
  • A trade-secrets fight. Usdin walked through Beam Therapeutics' September 25 lawsuit against China's Yoltec. Beam says a former scientist, Emma Wang, secretly co-founded Yoltec while still at Beam and used Beam's know-how to build a competing base-editing drug for alpha-1 antitrypsin deficiency, a genetic lung and liver disease. Beam lists 19 categories of allegedly stolen technology, including "negative know-how," meaning knowledge of what did not work. Usdin reached Yoltec, which called the claims "entirely without merit." He noted that Beam lost an arbitration over a similar claim against Prime Medicine in 2025, and warned that a trial would turn on "which side the jurors choose to believe" (BioCentury This Week).

Theme 3: Peptides, the FDA and who is really in charge

Five podcasts covered the same story: the Trump administration plans to let compounding pharmacies (pharmacies that mix their own versions of drugs) sell certain unapproved peptides while the FDA writes permanent rules. Peptides are short chains of amino acids sold for everything from healing to hair loss to "longevity."

  • FDA staff object. On Citeline's Drug Fix podcast, Pink Sheet reporter Maisha Osman said FDA reviewers in the drug center "have made clear internally that they would not recommend this." They worry the products have not been properly tested and that the move "could undermine the drug approval system." Executive editor Derek Ingerie called it the reverse of the old Plan B fight, when FDA said yes and HHS said no (Citeline Drug Fix).
  • An awkward spot for Overton. Osman said the announcement might come from the White House Domestic Policy Council, "where the commissioner nominee Heidi Overton works." Overton has said staff morale matters to her, and Osman said morale "is still not there" (Citeline Drug Fix).
  • The GLP-1 contradiction. Senior editor Sue Sutter pointed out that Lilly and Novo have pushed the FDA hard to crack down on compounded copies of their obesity drugs, while the government now plans to allow compounding of peptides that "have not undergone any clinical testing." She doubts it will shrink the gray market: copies of Lilly's retatrutide are already sold, and "that's not even been submitted yet" for approval (Citeline Drug Fix). Osman said six of the seven peptides reviewed at a July advisory meeting were recommended, by a panel whose members were largely picked by HHS Secretary Robert F. Kennedy Jr.
  • Mixed reactions elsewhere. On Health:Further, the hosts called it "a safety issue." They said some peptides "alter growth and cell regeneration... that's just a little close to cancer for me," and argued the FDA is "past the point of no return" on public trust. In the same week the Wall Street Journal reported that Chinese makers of fentanyl ingredients are selling bootleg peptides to Americans (Health:Further). Pharmacy Podcast Network's host took the opposite view, calling compounders "our protectors in the realm of peptides" because regulated pharmacies are safer than buying online (Pharmacy Podcast Network).
  • New FDA transparency plans. Ingerie also covered a blog post by acting FDA chief of staff Lowell Zeta. The FDA wants to start disclosing when drug applications (NDAs, BLAs and generic ANDAs) have been filed. That would require a new rule, because today the agency treats this as confidential business information. Sutter's caution: "It doesn't help us very much if you find out nine months after the fact" (Citeline Drug Fix).

Theme 4: Overton's FDA nomination stalls until after the midterms

  • Likely no vote before November. On The Federal Drive, FDA lawyer Jamie Ravitz of McDermott Will & Schulte said Overton "had her hearing, but probably isn't going to get voted on before the midterms." He said her hardest job will be "turning policy objectives into decisions that career scientists and regulators... can administer consistently." He pointed to the recent exit of Vinay Prasad, head of the FDA's biologics center, as an example of that tension. Her open issues include "vaccines, mifepristone, peptides, clinical trial reform, AI-enabled medical products" (The Federal Drive).
  • Staffing has partly recovered. Ravitz said "quietly, FDA has been rehiring a lot of the staff" that was put on leave, though "maybe not to the point where it was before" the DOGE layoffs (The Federal Drive).
  • Susan Collins as the swing vote. On Paging America, a left-leaning health policy show, the hosts called Overton's views on vaccines and abortion extreme. They noted the FDA's safety review of the abortion pill is not expected until March. They argued Collins "has the ability to sink that nomination with one vote" because Republicans hold just a one-vote majority on the Senate health committee (Paging America).

Theme 5: Drug pricing: the "GLOBE" plan shrinks, but the precedent stays

  • From $11.9 billion to about $440 million. BioCentury's Steve Usdin explained GLOBE, the administration's mandatory "most favored nation" pricing model for Medicare Part B, which covers drugs given in a doctor's office, mostly injectables. Most favored nation pricing ties US prices to the lower prices paid abroad. GLOBE was first pitched as saving $11.9 billion over seven years and has shrunk to about $440 million. CMS says it will hit only four undisclosed companies, and Usdin hears it may be just two. Companies that agreed to extend MFN pricing to Medicaid are exempt, as are gene and cell therapies, orphan-only drugs, plasma products and drugs facing biosimilar competition (BioCentury This Week).
  • Why it still matters. Usdin's main point: "the precedent really does matter more than the money here." Big pharma companies that signed MFN deals have publicly accepted foreign prices as a fair benchmark. When Democrats regain power, he expects them to cite that through the IRA's Medicare drug price negotiation program. A second precedent is "pharma CEOs... negotiat[ing] prices of particular drugs... with the President of the United States" (BioCentury This Week).
  • January 1 start date and likely lawsuits. GLOBE was pushed back to January 1. GUARD, the matching model for Medicare Part D retail drugs, also starts January 1. Usdin thinks "litigation is quite likely," probably from trade groups seeking to block both (BioCentury This Week).

Theme 6: Obesity drugs: Novo's CagriSema win comes with fine print, and Lilly looks past weight

  • CagriSema vs. Mounjaro in diabetes. On Fat Science, obesity doctor Emily Cooper took apart Novo's REIMAGINE 5 headline. CagriSema combines semaglutide (the drug in Ozempic and Wegovy) with cagrilintide, a man-made version of amylin, a pancreas hormone that tells the brain you have eaten. In people with type 2 diabetes over 60 weeks it produced 12.4% weight loss versus a little over 9% for Mounjaro, with blood sugar control that was "non-inferior," meaning about as good. The catch: both drugs were given at low doses, 1.0/1.0 mg CagriSema versus full doses of 2.4/2.4, and 5 mg Mounjaro versus a full 15 mg. Her verdict: "If they go out there with that claim, we beat Mounjaro on weight loss, that would be pretty hard for people to respect... you just picked these two arbitrary doses" (Fat Science).

  • A hint that lower doses may be enough. In REIMAGINE 9, in people without diabetes, the same low dose produced 21% weight loss, close to the 22.7% seen at the full dose in earlier trials. That suggests "maybe the dose doesn't need to be so high for a lot of patients." Cooper expects CagriSema approval in Q4 2026. She also reminded listeners that company headline numbers usually use the "efficacy estimand," which counts only people who stayed on the drug, "because they want to have bigger numbers" (Fat Science). Lilly's executive on what comes next. On Docs Who Lift, a Lilly cardiometabolic executive went through the pipeline:

  • Retatrutide (the triple-acting shot) produced up to 28.3% weight loss at 80 weeks, and "a little over 30%" in an extension group. Even the lowest 4 mg dose gave about 19% with "just a single dose titration step." In diabetes it lowered HbA1c (a three-month blood sugar measure) by up to 2 points (Docs Who Lift).

  • On price: "I don't think you should interpret the conversation around BLA as that Lilly is looking to pursue specialty drug price points for this medicine." He pointed to the new Medicare Bridge Program, under which seniors with obesity can get Zepbound and similar drugs "for just a $50 a month copay," and said Lilly data show patients "are saving enough in healthcare expenses to more than offset the cost" after a year (Docs Who Lift).

  • Room to grow: global use is "maybe 2 to 3% utilization... relative to the total population of appropriate patients." The pill orforglipron is meant to be made "with more sort of traditional chemical synthesis approaches, like what we use for blood pressure pills and statins," so it can scale. A new orforglipron study, ATTAIN-NOW, tests whether it can stop people with a BMI of 25 or more and early risk factors from progressing (Docs Who Lift).

  • The amylin drug: eloralintide on its own cut HbA1c by "over a full percentage point from an average baseline of about 8.14," and combined with tirzepatide by about 2.9 points. Phase 3 started late last year; "add a couple years to the start date to see Phase 3 data" (Docs Who Lift).

  • The rulebook is out of date: FDA obesity guidelines are "still centered around this 5% weight loss relative to placebo... now that we have agents pushing 20, 25, close to 30%, probably it's time to revisit that," and he questioned whether placebo "is even a relevant comparator." He said Lilly's muscle-preserving drug bimagrumab is now in a new Phase 2 study with tirzepatide (Docs Who Lift).

  • Not everything works. On DOC Updates, obesity researcher Donna Ryan listed the benefits beyond weight: a 20% cut in heart attacks and strokes in the SELECT trial, and tirzepatide's approval for sleep apnea. She also listed the setbacks, including failed large Alzheimer's trials of oral semaglutide (EVOKE/EVOKE+) and Parkinson's trials (DOC Updates).

  • A miss in heart disease. Fat Science also covered Novartis's pelacarsen trial (HORIZON), which included over 8,000 patients with heart disease and high lipoprotein(a), an inherited cholesterol-like particle. The drug cut Lp(a) by about 80%, but heart attacks, strokes and heart deaths "did not go down significantly." Cooper asked whether Lilly's lepodisiran, which lowers Lp(a) by about 94% and has results due around 2029, might do better, or whether lowering Lp(a) simply does not help (Fat Science).

Theme 7: Cancer data: Epkinly beats expectations, and ivonescimab's Western data is good but modest

  • Epkinly in frontline lymphoma. BioSpace's Heather McKenzie said Genmab and AbbVie's Epkinly, a bispecific antibody (one antibody that grabs two targets), added to standard R-CHOP chemotherapy cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. Analysts had expected 30–35%. Roche's Polivy got approval in the same setting with 27%, and Incyte's Monjuvi hit 25% earlier this year. William Blair said the result "knocks it out of the park." Truist called it "highly differentiated" but wants durability, survival and safety data; the trial wraps up in June 2027 (BioSpace).
  • Ivonescimab in EGFR-mutant lung cancer. On Oncology Brothers, City of Hope lung cancer specialist Christine Lovly reviewed the global HARMONi data for Summit's ivonescimab, a bispecific that blocks both PD-1 (an immune checkpoint) and VEGF (a blood-vessel growth signal). In patients whose cancer worsened on targeted pills, median overall survival was 17.5 months versus 14 months for chemo alone. Importantly, the benefit showed up "in both Asian and Western populations." Her view: "it is technically statistically significant, whether it's clinically meaningful, we can debate that." She called it an "entry point" for immunotherapy in this type of lung cancer, which has not used it before, but said it is unclear "is it the PD-1 arm or is it the VEGF arm" driving the result, and that newer antibody-drug conjugates are racing for the same spot (Oncology Brothers).
  • Other lung cancer notes from Lovly: Eight-year ADAURA data hold up osimertinib after surgery (79% vs 64% survival). Small cell lung cancer, a disease with almost no progress for decades, now has "a whole slew" of options, and "the days of nihilism for small cell are gone." Lovly calls subcutaneous tarlatamab "a game changer." For HER2-mutant lung cancer she uses the oral drug zongertinib first rather than Enhertu (T-DXd), because of the risk of lung inflammation (Oncology Brothers).
  • A colon cancer first. Pharmacy Podcast Network reported FDA approval of the first immunotherapy-based regimen for stage 3 colon cancer after surgery, for patients whose tumors test positive for a DNA repair defect (dMMR) (Pharmacy Podcast Network).

Theme 8: Cell therapy loses favor with investors

  • Caribou shuts down. On The Readout Loud, STAT's Adam Feuerstein said Caribou Biosciences is closing after failing to raise money for a Phase 3 trial of its off-the-shelf, CRISPR-edited CAR-T therapy for lymphoma. CAR-T therapy re-engineers immune cells to attack cancer, and "off-the-shelf" means made from donor cells in bulk rather than from each patient. CEO Rachel Haurwitz told him investors were "either not interested in funding cell therapies, or they just don't believe in the concept." Feuerstein's diagnosis: "they just missed their moment." Gilead, Bristol Myers and J&J have all bought into "in vivo" CAR-T, where the cells are engineered inside the patient's body, "and so they've kind of just boxed out the off-the-shelf companies like Caribou" (The Readout Loud).
  • The funding data agree. On Inside Biotech, BCLA's Eileen Zhang said early-stage venture money for cell therapy and immunotherapy fell from $170 million to $131 million, and for gene editing from $28 million to $19 million. That decline has been steady "since 2021," driven by "fading confidence" and disappointing results for CAR-T in solid tumors (Inside Biotech).
  • The commercial side is still growing. On Pharmacy Podcast Network, Joe DePinto of McKesson's InspiroGene said 2026 is "on track... to have around the same approvals as last year," and that FDA moves to drop safety programs (REMS) and shorten required patient stays near treatment centers "have really helped." Treatment is moving from academic centers to community hospitals and some outpatient clinics (Pharmacy Podcast Network).

Theme 9: Money is flowing, but only to late-stage drugs

  • Early rounds shrink, later rounds grow. Zhang said US seed and Series A funding fell from $1.6 billion to $1 billion, while Series B rose to about $7 billion from $5 billion. Licensing and M&A were up about 75%, and global licensing jumped from $8 billion to $25 billion. Examples included a $287 million Series D for a developer of oral GLP-1 obesity pills, Slate Medicine's $130 million Series A for a migraine antibody, and Gilead's roughly $8 billion purchase of Arcellx (Inside Biotech).
  • Fast Money agreed: big pharma is "not buying flyers anymore. They're buying phase two, late phase two, phase three assets," and Flavin said private investors are also crowding into late-stage deals (Fast Money).
  • Europe turns to venture debt. On a BioSpace "Denatured" episode, Joey Mason of Claret Capital and a European VC argued Europe's funding gap is structural. US pension funds put 2% to 5% into private equity, versus a tiny fraction in Europe, and Europe lacks big university endowments. Mason said venture debt costs roughly 14%, versus a cost of equity "in the mid-30s," and fits best around the end of Phase 2 (BioSpace).
  • Medicines made in space. Varda Space Industries raised $251 million to manufacture medicines in orbit (BioSpace).

Theme 10: The biotech index is up, but the people who own biotech stocks are losing money

  • The paradox. STAT's Elaine Chen noted the XBI is up 23% this year. Feuerstein: "when I talk to investors now, they are like seriously depressed." The reason is that the stocks specialists own most, the "crowded longs," have lagged "particularly since August." Meanwhile the stocks they bet against are rising: "they're losing money on the stocks that they own. They're losing money on the stocks that they're shorting." His example is Moderna. It is one of the index's best performers, but nearly all the gain came after its August cancer vaccine data, when "a lot of investors were actually shorting." He added that tech- and AI-flavored names in the index, which few biotech specialists own, have done much of the lifting (The Readout Loud).
  • Rising rates are the headwind. Feuerstein said rising interest rates make it harder to raise money, which "is the thing that biotech companies probably do best" (The Readout Loud). Fazeli on Bloomberg Intelligence: the XBI "more than doubled over the past... year and a bit... You've got AI competing with it. You've got interest rates competing with it" (Bloomberg Intelligence). On Motley Fool Hidden Gems, with the 10-year Treasury yield near 5.2%, a host argued cash-rich Lilly and Regeneron could actually benefit from higher yields (Motley Fool Hidden Gems).
  • Big pharma has slipped too. Fast Money said "pharma stocks have slid in the past month after a slew of clinical trial setbacks and as investors rotate out of the sector" (Fast Money).

Theme 11: NIH funding: the money came through, but the uncertainty did not go away

  • On The Readout Loud, STAT's Anil Oza said the NIH spent its full external grant budget in fiscal 2026 after Congress blocked the 40% cut President Trump wanted. The problem now is how it spends. Under NIH Director Jay Bhattacharya's "Unified Funding Strategy," peer-review scores matter less, program officers have more say, and funding is aligned with political goals. Heather Pierce of the Association of American Medical Colleges said fewer people started biomedical PhD programs in 2025 than in 2024 at many schools: "It will take many years to understand what impact these two years have had" (The Readout Loud).
  • University of Washington TB researcher Chetan Seshadri described the human cost: "By May of 2025, I had zero dollars in NIH funding. Every single grant I had was terminated, delayed, or frozen" (The Readout Loud).

(2) Active Debates

Is AstraZeneca's Summit stake a smart hedge or a sign of doubt?

  • Hedge view: Sam Fazeli (Bloomberg Intelligence) said AZ "kind of hedged its bet to a degree... Astra's not taking the asset," and noted AZ "supposedly had approached them about a year ago for a $15 billion acquisition that never happened." He said CEO Bob Duggan, who sold Pharmacyclics to AbbVie for "something in the region of 20-odd billion dollars," has the money and conviction to wait (Bloomberg Intelligence).
  • The split on the drug class: "Some people believe that it's the biggest thing that's going to happen since Merck brought... Keytruda... And others think, well, we haven't seen enough data." Christine Lovly's read of the Western HARMONi data, a 3.5-month survival gain, puts her closer to the cautious camp: "whether it's clinically meaningful, we can debate that" (Oncology Brothers).

Merck vs. Bristol Myers: who handles the patent cliff better?

  • Merck (bullish): BMO's Evan Seigerman told BioSpace he is most bullish on Merck's plan, citing the Moderna-partnered mRNA cancer vaccine, the already-approved lung blood pressure drug Winrevair, and the TROP2 antibody-drug conjugate sac-TMT licensed from Kelun-Biotech (BioSpace).
  • BMS (bearish): BMS must replace both Opdivo and the blood thinner Eliquis, and its replacements are riskier. Cobenfy "hasn't been selling as well as anticipated," Alzheimer's psychosis data are "pretty risky," and milvexian and a lung fibrosis drug carry "so much riding on these assets" (BioSpace). Jim Cramer reached the same view on Squawk on the Street: "unless you have a pipeline that's kind of like a Lilly, you're going to be left behind. And I think Bristol now is going to be very much left behind. I don't think you can buy it" (Squawk on the Street).

Should unapproved peptides be sold through compounding pharmacies?

  • For: The compounding trade group argues regulated, inspected pharmacies are safer than the illicit market (Citeline Drug Fix). Pharmacy Podcast Network: "I think that our compounders are our protectors" (Pharmacy Podcast Network). On The Dr Vonda Show, Dr. Darshan Shah argued drugmakers won't fund trials for compounds they cannot patent (The Dr Vonda Show).
  • Against: FDA reviewers, the Pink Sheet team and Health:Further all say the products are untested, that the move undercuts the approval system, and that it contradicts the crackdown on compounded GLP-1s (Citeline Drug Fix, Health:Further).

Is the rush into China healthy, or a security risk?

  • Healthy, and the fix is at home: Flavin says the US should "do a better job of creating the environment to compete... Not so much try to control markets" (Fast Money).
  • Risky if it becomes co-development: Usdin says Congress's worry is Western firms helping Chinese companies build capabilities to compete later, and more co-development deals will invite tighter Treasury rules (BioCentury This Week).

Do company headline numbers on obesity drugs mean what they seem?

  • Emily Cooper (Fat Science) argued that "efficacy estimand" headlines and low-dose comparisons like REIMAGINE 5 flatter the results (Fat Science). Lilly's executive argued the opposite problem: the regulatory bar (5% versus placebo) is too low for today's drugs and should be rethought (Docs Who Lift).

(3) Stock-by-Stock Bull/Bear

Company Bull case (who said it) Bear case (who said it)
Eli Lilly (LLY) Lilly faces no major patent cliffs (BioSpace's Gabrielle Masson). Retatrutide reaches ~28–30% weight loss; global use of these drugs is only 2–3% of eligible patients; the orforglipron pill is built to scale (Lilly exec, Docs Who Lift). "Lily is just crushing it" (John Flavin, Fast Money). Gray-market retatrutide is already sold before filing (Sue Sutter, Citeline). Pricing pressure as Medicare pays a $50 copay (Docs Who Lift).
Novo Nordisk (NVO) "Hold for a long time and likely you'll be rewarded" (Flavin, Fast Money). CagriSema approval expected Q4 2026 (Emily Cooper, Fat Science). "Cannot get a bid no matter how much they sell" (Fast Money host). "Everything that Novo does to try to catch up, Lilly's got 10 times the weight" (Flavin). CagriSema's Mounjaro win relied on low doses (Cooper).
Merck (MRK) BMO's Seigerman is most bullish on Merck's patent-cliff plan (BioSpace). Cramer expects the melanoma vaccine market to be "far larger," with data around Oct 23; Merck is the No. 3 Dow stock this year (Squawk on the Street). Keytruda patent exposure is among the largest in pharma (BioSpace).
Bristol Myers Squibb (BMY) "Sure, it's an inexpensive stock" (Cramer). Most bearish big pharma at BMO; must replace Opdivo and Eliquis with riskier assets (Seigerman, BioSpace). Downgraded to hold on Cobenfy doubts in Alzheimer's psychosis; "very much left behind" (Cramer, Squawk on the Street).
AbbVie (ABBV) / Genmab (GMAB) Epkinly cut progression risk 51% vs. 30–35% expected; "knocks it out of the park" (William Blair, via BioSpace). Truist wants durability, survival and safety data before judging absolute benefit; trial ends June 2027 (BioSpace).
Summit Therapeutics (SMMT) / AstraZeneca (AZN) $2B AZ equity stake; some see the class as the next Keytruda (Fazeli, Bloomberg Intelligence). Benefit seen in Western patients (Lovly). "We haven't seen enough data" (skeptics, via Fazeli). 17.5 vs. 14 months survival; "whether it's clinically meaningful, we can debate that" (Lovly, Oncology Brothers).
Regeneron (REGN) / Sanofi (SNY) $1B upfront plus up to $7B in milestones for four Dupixent successors; lawsuit settled (BioSpace). Cash-rich Regeneron may benefit from higher yields (Motley Fool). Key Dupixent US patent expires 2031; relationship described by BMO as "sometimes contentious" (BioSpace).
Novartis (NVS) Abogen deal adds an in-body T-cell engager and validates its RNA strategy (BioSpace). Pelacarsen Lp(a) outcomes trial missed despite ~80% Lp(a) cut (Fat Science).
Moderna (MRNA) One of the best XBI performers since August's cancer vaccine data (Feuerstein, Readout Loud); key data at a conference in about three weeks (Fazeli). Fazeli joked about the "cancer vaccine that's going to treat every cancer," a hint that expectations are high going into the data.
Sarepta (SRPT) Jefferies sees a turnaround: Elevidys showed durable benefit in older DMD boys at the World Muscle Society; Arrowhead-partnered DM1 and FSHD drugs could each top $1B (BioSpace). Stock near or below $20 vs. over $150 in 2024. Exon-skippers Amondys 45 and Vyondys 53 failed a confirmatory motor trial, and approval rests on real-world data (BioSpace).
Viking Therapeutics (VKTX) Up 30% in September on maintenance data Truist called "the best case scenario" (BioSpace). A stock and convertible note offering a day later pulled the shares back (BioSpace).
Vertex (VRTX) ~$10B Crinetics deal opens a hormone-disease business (BioSpace). A rare large deal for a company that seldom buys (BioSpace).
Beam Therapeutics (BEAM) Seeking an injunction against Yoltec's competing AATD base editor (BioCentury). Lost an earlier trade-secret arbitration against Prime Medicine; the case "is going to be a lot more complex" than coverage suggests (Steve Usdin, BioCentury).
Caribou Biosciences (CRBU) No bull case was made. Shutting down after failing to fund Phase 3; "missed their moment" (Feuerstein, Readout Loud).
Humana (HUM) Shares rose about 15% on improved Medicare Advantage star ratings (Bloomberg Daybreak). No bear case was made.
Iovance (IOVA) Used as a hypothetical buyout example on a careers podcast (Random Musings). Speculative only.

(4) Notable Quotes

"When I talk to investors now, they are like seriously depressed. What's weird about this is the XBI is doing pretty okay."

Adam Feuerstein, STAT (The Readout Loud)

"I think it was more the fact that they just missed their moment."

Adam Feuerstein on Caribou's shutdown (The Readout Loud)

"The precedent really does matter more than the money here."

Steve Usdin, BioCentury, on the shrunken GLOBE pricing model (BioCentury This Week)

"Some people believe that it's the biggest thing that's going to happen since Merck brought this drug to market called Keytruda... And others think, well, we haven't seen enough data."

Sam Fazeli, Bloomberg Intelligence, on Summit's ivonescimab (Bloomberg Intelligence)

"It is technically statistically significant, whether it's clinically meaningful, we can debate that."

Dr. Christine Lovly, City of Hope, on HARMONi (Oncology Brothers)

"Unless you have a pipeline that's kind of like a Lilly, you're going to be left behind. And I think Bristol now is going to be very much left behind."

Jim Cramer (Squawk on the Street)

"Everything that Novo does to try to catch up, Lilly's got 10 times the weight in answers."

John Flavin, Portal Innovations (Fast Money)

"Now that we have agents pushing 20, 25, close to 30%, probably it's time to revisit that. And first of all, ask whether placebo is even a relevant comparator."

Lilly cardiometabolic executive (Docs Who Lift)

"You just picked these two arbitrary doses, and they're not, neither one's a full dose."

Dr. Emily Cooper on Novo's CagriSema vs. Mounjaro claim (Fat Science)

"The FDA staff, particularly within CDER, they have made clear internally that they would not recommend this."

Maisha Osman, Pink Sheet, on compounded peptides (Citeline Drug Fix)

"I fear that the FDA... is really past the point of no return anyway."

Health:Further host (Health:Further)

"By May of 2025, I had zero dollars in NIH funding. Every single grant I had was terminated, delayed, or frozen."

Dr. Chetan Seshadri, University of Washington (The Readout Loud)

"They had a whole legal dispute. They're like, we're all good now. We'll just throw another several billion at them."

Jeff Axt, BioSpace, on Sanofi and Regeneron (BioSpace)

(5) Catalysts to Watch

Date Event Where it came up
~Oct 23–late Oct 2026 Merck/Moderna mRNA melanoma vaccine data at a medical conference; Cramer and Fazeli both flagged it Squawk on the Street, Bloomberg Intelligence
Nov 3, 2026 (midterms) and after Senate vote on FDA nominee Heidi Overton, expected after the election The Federal Drive, Paging America
Pending HHS/White House temporary order allowing compounded unapproved peptides Citeline Drug Fix
Q4 2026 Expected FDA decision on Novo's CagriSema Fat Science
Jan 1, 2027 GLOBE (Medicare Part B) and GUARD (Part D) most-favored-nation pricing models start; lawsuits seeking to block them are likely BioCentury This Week
Feb 28, 2027 FDA decision on traditional approval for Sarepta's Amondys 45 and Vyondys 53 BioSpace
March 2027 FDA safety review of the abortion pill mifepristone expected Paging America
Not yet scheduled Sarepta Phase 1/2 readouts in DM1 and FSHD (Arrowhead-partnered) BioSpace
Not yet scheduled Lilly bimagrumab plus tirzepatide Phase 2 results Docs Who Lift
June 2027 Epkinly frontline DLBCL Phase 3 completes, with full durability and survival data BioSpace
Not yet scheduled Treasury rules on how biotech fits into the COINS Act outbound-investment framework BioCentury This Week
~2029 Lilly lepodisiran Lp(a) outcomes data Fat Science